A new group of antibody–drug conjugates (ADCs) has been developed by the research team from The Scripps Research Institute (TSRI) using an adaptable “double
A new group of antibody–drug conjugates (ADCs) has been developed by the research team from The Scripps Research Institute (TSRI) using an adaptable “double